COMPOSITION PHARMACEUTIQUE DESTINÉE À LA PRÉVENTION ET AU TRAITEMENT DE BRONCHOPNEUMOPATHIES CHRONIQUES OBSTRUCTIVES, CONTENANT UN EXTRAIT D'HENOSIS STAPF DE LA VAR. MUNRO DE PHYLLOSTACHYS NIGRA EN TANT QUE PRINCIPE ACTIF
UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY
发明人:
KIM, JINJU,KO, EUNJUNG,LEE, EUI JEONG
申请号：
EP13764343
公开号：
EP2875823A4
申请日:
2013.03.06
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
The present invention relates to a pharmaceutical composition for the prevention and treatment of chronic obstructive pulmonary disease (COPD) comprising the extract of Phyllostachys nigra Munro var. henosis Stapf as an active ingredient. Particularly, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can reduce the numbers of macrophages and neutrophils increased in bronchoalveolar lavage fluid (BALF) and is effective in preventing weight loss caused by chronic obstructive pulmonary disease and is effective in down-regulating significantly IL-6, TNF-±, IL-1², MCP-1, and MMP-12, which are rapidly increased in bronchoalveolar lavage fluid, intrapulmonary tissue, and serum according to the development of chronic obstructive pulmonary disease. In addition, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention has the effect of blocking the activation of NF-ºB signal in intrapulmonary tissue and significantly reduces inflammatory cells in the tissues around alveoli as well as significantly reduces the size of the enlarged alveola. Therefore, the extract of Phyllostachys nigra Munro var. henosis Stapf of the present invention can be effectively used as an active ingredient of medicines and health food for the prevention and treatment of chronic obstructive pulmonary disease.
